drugset / Trial / NCT07233642
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Timeline
- Start
- 2025-11
- Primary completion
- 2026-05
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T cells | Cell therapy | 150000 cells/kg | — |
| Subject | CD19 CAR-T cells | Cell therapy | 500000 cells/kg | — |
| Subject | CD19 CAR-T cells | Cell therapy | 1e+06 cells/kg | — |